Acadia Pharmaceuticals (ACAD) PT Raised to $38 at Citizens JMP

Citizens JMP analyst Jason Butler raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $38.00 (from $37.00) while maintaining a Market Outperform rating.

The analyst commented,"Solid commercial performance reflects success of strategic optimizations and investments; we reiterate our Market Outperform rating on Acadia Pharmaceuticals and increase our risk- adjusted, DCF-derived price target to $38 from $37. Yesterday afternoon, Acadia reported 2Q25 financial results ahead of our and consensus estimates with in-line NUPLAZID sales and DAYBUE driving the top-line beat. Management raised the lower end of the revenue guidance range due to continued NUPLAZID strength. Key pipeline catalysts remain on track and the near-term focus is on Phase 3 results for ACP-101 in Prader-Willi Syndrome (PWS) in early 4Q25."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Stripe, Advent In Talks To Buy Paypal - WSJ